The MCCC considers the developmental funds as one of the most critical components of CCSG support. Together with institutionally derived Cancer Center discretionary funds and the annual grant support from the Fraternal Order of Eagles, these funds provide seed monies necessary to either initiate research projects or generate pilot data for subsequent grant applications. It should not be surprising, given the small size of the developmental fund pool ($175,000/yr) relative to the substantial expansion realized over the last funding period, that Mayoprovided discretionary funds have contributed more than 90% of the monies needed for seed or pilot projects, for program or shared resource initiation, and all funds for instrumentation and new laboratory set-up costs. Funding is requested in the next project period to support initiatives in the following categories: new cores; equipment; recruitment; and pilot projects. The Cancer Center's review and planning process is rigorous. Investigator-initiated and programmatic proposals must demonstrate a clear probable trajectory for sustained peer reviewed funding, and proposals for enhancement of our shared resources must be for quality services or technologies that address a critical current or projected need - they must add value. The Center has also recognized the importance of these funds in support of high risk projects that might otherwise not be accorded funding through traditional peer review. These projects are particularly encouraged by the MCCC. Nonetheless, they must meet the same scientific standards as other proposals as a prerequisite for funding consideration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-30
Application #
6989932
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-15
Project End
2009-02-28
Budget Start
2004-09-15
Budget End
2005-02-28
Support Year
30
Fiscal Year
2004
Total Cost
$200,000
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99

Showing the most recent 10 out of 1129 publications